Cas:904814-72-8 3-Bromo-2-phenylimidazo[1,2-a]pyrimidine manufacturer & supplier

Chemical Name:3-Bromo-2-phenylimidazo[1,2-a]pyrimidine

CAS.NO:904814-72-8

Synonyms:3-bromo-2-phenylimidazo[1,2-a]pyrimidine

Molecular Formula:C₁₂H₈BrN₃

Molecular Weight:274.11600

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.58g/cm3

Index of Refraction:1.712

PSA:30.19000

Exact Mass:272.99000

LogP:3.15880

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-bromo-2-phenylimidazo[1,2-a]pyrimidine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-bromo-2-phenylimidazo[1,2-a]pyrimidine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-bromo-2-phenylimidazo[1,2-a]pyrimidine Use and application,3-bromo-2-phenylimidazo[1,2-a]pyrimidine technical grade,usp/ep/jp grade.

Related News: The pharmaceutical industry is related to the national economy and the people’s livelihood. The entire upstream and downstream areas involve all aspects of the national economy. Our government has a long-term direct or indirect policy preference for this. 3-Bromo-2-phenylimidazo[1,2-a]pyrimidine manufacturer The researchers found that compared with those with cancer, the prevalence of FT was higher among those with ASCVD (54 versus 41 percent). In adjusted analyses, when studying individual components of FT, those with ASCVD had increased odds of any difficulty paying medical bills, inability to pay bills, cost-related medication nonadherence, food insecurity, and foregone/delayed care due to cost (odds ratios, 1.22, 1.25, 1.28, 1.39, and 1.17, respectively). 3-Bromo-2-phenylimidazo[1,2-a]pyrimidine supplier The researchers found that compared with those with cancer, the prevalence of FT was higher among those with ASCVD (54 versus 41 percent). In adjusted analyses, when studying individual components of FT, those with ASCVD had increased odds of any difficulty paying medical bills, inability to pay bills, cost-related medication nonadherence, food insecurity, and foregone/delayed care due to cost (odds ratios, 1.22, 1.25, 1.28, 1.39, and 1.17, respectively). 3-Bromo-2-phenylimidazo[1,2-a]pyrimidine vendor Additional results from the trial with data on another goal of extending survival is expected in 2020, AstraZeneca said. 3-Bromo-2-phenylimidazo[1,2-a]pyrimidine factory In March 2021, Reuters reported that a former Lilly human resources officer, Amrit Mula, had identified internally some of the same violations later documented by the FDA. Mula was forced out of the company in early 2019 after Lilly executives sought to downplay her findings, according to a letter demanding compensation for damages that her attorneys sent to the company.